Summary of aTyr Pharma, Inc. (NASDAQ:LIFE) Ratings on Jun 27, 2018

June 27, 2018 - By Lena Young

aTyr Pharma, Inc. (NASDAQ:LIFE) Corporate Logo

aTyr Pharma, Inc. (NASDAQ:LIFE) Ratings Coverage

A total of 3 analysts rate aTyr Pharma (NASDAQ:LIFE) as follows: 0 “Buy”, 0 “Hold” and 3 “Sell”. Тherefore 0 are bullish. (NASDAQ:LIFE) has 3 ratings reports on Jun 27, 2018 according to StockzIntelligence. On Wednesday, February 14 JP Morgan downgraded aTyr Pharma, Inc. (NASDAQ:LIFE) to “Underweight” rating. The stock rating was downgraded by Citigroup to “Sell” on Tuesday, May 15. In Wednesday, February 14 report J.P. Morgan downgraded the stock to “Sell” rating. Listed here are aTyr Pharma, Inc. (NASDAQ:LIFE) PTs and latest ratings.

15/05/2018 Broker: Citigroup Rating: Sell New Target: $1.0000 Downgrade
14/02/2018 Broker: J.P. Morgan Rating: Sell Downgrade
14/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Downgrade

Ticker’s shares touched $1.01 during the last trading session after 8.18% change.aTyr Pharma, Inc. is downtrending after having declined 72.94% since June 27, 2017. LIFE has 3.42 million volume or 385.71% up from normal. The stock underperformed the S&P500 by 85.51%.

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine therapeutics for patients suffering from severe and rare diseases.The firm is valued at $30.13 million. The firm develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy , early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy.Currently it has negative earnings. The Company’s discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines.

There’s an important aTyr Pharma, Inc. (NASDAQ:LIFE) news announced by Globenewswire.com. It’s an item titled: “aTyr Pharma to Present at Jefferies 2018 Global Healthcare Conference” on May 31, 2018.

aTyr Pharma, Inc. (NASDAQ:LIFE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.